Here is how MacroGenics (MGNX) and CareDx (CDNA) have performed compared to their sector so far this year.

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Discovery Fund”. A copy of the letter is available to download here. Baron Discovery Fund appreciated by 19.08% (Institutional Shares) in the quarter, underperforming the Russell 2000 Growth Index, which gained 25.71%. This lag was primarily due to a momentum-driven “AI […]

CareDx (CDNA) has surged 300% over the past year, driven by robust technical momentum and strong buy signals. CDNA is rated a “Strong Buy” by several analysts, with consensus price targets suggesting up to 12% further upside. Revenue is projected to grow 30.38% this year, with earnings expected to rise...

Snowflake and CareDx received favorable reviews from Wall Street firms, following better-than-expected second-quarter prints and bullish momentum across AI products, respectively.

The diagnostics leader is accelerating the trend toward precision medicine.

A bank stock hits an all-time high while a medical test provider reaches a buy point of an unusual bullish chart pattern.

Replimune (REPL) stock soared 94% after the company late Thursday reported a favorable outcome of th

CareDx (NASDAQ:CDNA) reported second-quarter 2026 revenue growth of 52% as the transplant diagnostics company expanded testing services, completed the sale of its lab products business and began integrating the recently acquired NavDx specialty oncology platform. Total revenue rose to $132 million

CareDx (CDNA) delivered earnings and revenue surprises of +68.18% and +15.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CareDx, Inc. previously announced that Medicare finalized a Local Coverage Determination for molecular testing to monitor solid organ transplant rejection, affirming coverage for its AlloSure Kidney, AlloMap and AlloSure Heart, and AlloSure Lung surveillance tests with defined testing limits over the first three years post-transplant. This decision removes a key reimbursement uncertainty for CareDx’s core transplant-testing portfolio, clarifying how frequently clinicians can use these...

CareDx (CDNA) is back in focus after Medicare finalized a Local Coverage Determination for molecular testing in solid organ transplants, confirming reimbursement for the company’s kidney, heart, and lung transplant surveillance portfolio. See our latest analysis for CareDx. The finalized Medicare LCD arrives after a sharp swing in sentiment around CareDx, with a 30 day share price return of 69.21% and a 1 year total shareholder return of 233.45%, even though the 5 year total shareholder...

CareDx stock has delivered a very strong 273.8% return over the past three years. However, its current valuation checks and recent share price strength point to a stock that may now be leaning expensive rather than clearly mispriced. Over the last three years, CareDx has returned 273.8%. This puts extra focus on whether the current price still reflects a reasonable balance between potential and risk. The finalization of Medicare coverage for CareDx’s solid organ transplant molecular tests...

CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Final Medicare policy supports transplant surveillance portfolioCareDx Inc. (NASDAQ:CDNA) shares climbed 20% on Thursday after the company announced that Medicare had finalized its Local Coverage Determination (LCD) covering molecular testing for solid organ transplant rejection.